Brand Name Prescription Drug Pricing

Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies
Publisher : National Academies Press
Page : 235 pages
File Size : 48,7 Mb
Release : 2018-03-01
Category : Medical
ISBN : 9780309468084

Get Book

Making Medicines Affordable by National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies Pdf

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.

Author : Peter J. Neumann,Joshua T. Cohen,Daniel A. Ollendorf
Publisher : Oxford University Press
Page : 312 pages
File Size : 41,6 Mb
Release : 2021-05-06
Category : Medical
ISBN : 9780197512906

Get Book

The Right Price by Peter J. Neumann,Joshua T. Cohen,Daniel A. Ollendorf Pdf

The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only intensify. The Right Price sheds light on the controversial topic of drug pricing by providing an accessible guide to pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It illustrates the need for value-based pricing through real-life stories of patients and their experiences with the drug industry and explains why simple solutions like price controls and the importation of cheaper drugs from other countries are problematic. This volume describes how researchers and policy makers have pursued drug valuation efforts in the past, and lays out a series of recommendations, based on years of shared author experience serving on national drug policy platforms, for how to further improve pharmaceutical value assessment in the United States. With unique industry insights and clear narrative, The Right Price unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value.

Author : Elias B. Toft
Publisher : Nova Snova
Page : 248 pages
File Size : 42,8 Mb
Release : 2020-03-13
Category : Electronic
ISBN : 1536176680

Get Book

Prescription Drug Pricing: Background, Discount Programs and Cost Lowering Strategies by Elias B. Toft Pdf

Chapter 1 examines the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on the Federal and state budgets, and on American families. Chapter 2 addresses frequently asked questions about government and private-sector policies that affect drug prices and availability. Among the prescription drug topics covered are federally funded research and development, regulation of direct-to-consumer advertising, legal restrictions on reimportation, and federal price negotiation. The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs at discounted prices to covered entitiesâeligible clinics, hospitals, and othersâin order to have their drugs covered by Medicaid. Covered entities are only allowed to provide 340B drugs to certain eligible patients. Chapter 3 reviews the Health Resources and Services Administration's (HRSA) oversight of the 340B Program to ensure compliance with program rules. In 2017, nearly 60% of U.S. adults aged 18â64 reported being prescribed medication in the past 12 months. Approximately 70% of prescription medications carry out-of-pocket costs. Strategies to reduce prescription drug costs at the individual level are discussed in chapters 4 and 5. Each year, Americans pay more for prescription drugs, and rising drug prices have a disproportionate impact on older Americans. Chapter 6 examines the history of rising drug prices for the brand-name drugs most commonly prescribed for seniors. Generic drugsâcopies of brand-name drugsâlead to significant cost savings. Before a generic drug can be marketed, FDA must approve the generic drug application. According to FDA, applications go through an average of three cycles of review before being approved, which may take years. Chapter 7 examines 1) the first review cycle approval rate of generic drug applications in recent years and factors that may have contributed to whether applications were approved; and 2) changes FDA has made to increase the first review cycle approval rate.

Author : United States. Congress. Senate. Committee on Commerce, Science, and Transportation. Subcommittee on Consumer Affairs, Foreign Commerce, and Tourism
Publisher : Unknown
Page : 102 pages
File Size : 50,5 Mb
Release : 2003
Category : Consumer protection
ISBN : STANFORD:36105050296339

Get Book

Comparative Pricing of Prescription Drugs Sold in the United States and Canada and the Effects on U.S. Consumers by United States. Congress. Senate. Committee on Commerce, Science, and Transportation. Subcommittee on Consumer Affairs, Foreign Commerce, and Tourism Pdf

Author : Jonathan R. Dickson,Amy M. Woebler
Publisher : Unknown
Page : 0 pages
File Size : 53,7 Mb
Release : 2011
Category : Medical economics
ISBN : 1613246390

Get Book

Prescription Drug Pricing by Jonathan R. Dickson,Amy M. Woebler Pdf

The growing cost of brand-name prescription drugs can be a burden on patients, payers and providers of health care, particularly when price increases are large and occur suddenly. Controlling rising prescription drug prices helps to ensure that patients can afford medically necessary and sometimes life-saving medication, and to moderate costs for hospitals and third-party payers such as insurance plans and state and federal governments. This book examines prescription drug pricing costs and control concerns with a focus on extraordinary price increases for brand-name prescription drugs, as well as the characteristics and factors that contributed to this price increase.

Author : Elizabeth R. Nesbitt
Publisher : DIANE Publishing
Page : 246 pages
File Size : 53,5 Mb
Release : 2000
Category : Drugs
ISBN : 9781457823428

Get Book

Pricing of Prescription Drugs by Elizabeth R. Nesbitt Pdf

Author : John E. Dicken
Publisher : DIANE Publishing
Page : 28 pages
File Size : 47,6 Mb
Release : 2011-08
Category : Medical
ISBN : 9781437983050

Get Book

Prescription Drugs by John E. Dicken Pdf

Prescription drug spending in the U.S. in 2009 totaled $250 billion, of which $78 billion -- or 31% -- was spent by the fed. gov¿t. Prescription drug spending by the fed. gov¿t., patients, and third-party payers, including employers, is driven by many factors, including the prices paid for drugs. This report: (1) examines U&C price trends for commonly used prescription drugs from 2006 through the first quarter of 2010 and compares these trends to those of other medical consumer goods and services; and (2) examines price trends using drug prices other than U&C. Also provides info. on the extent to which prices for individual brand-name drugs changed over the course of this analysis period. Charts and tables. This is a print on demand report.

Author : Robin Feldman
Publisher : Cambridge University Press
Page : 203 pages
File Size : 43,6 Mb
Release : 2023-10-31
Category : Law
ISBN : 9781009432948

Get Book

Drugs, Money, and Secret Handshakes by Robin Feldman Pdf

Examines the pharmaceutical industry to expose how higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines.

Author : John E. Dicken
Publisher : Unknown
Page : 19 pages
File Size : 43,6 Mb
Release : 2012
Category : Drugs
ISBN : OCLC:804860826

Get Book

Drug pricing by John E. Dicken Pdf

Author : United States Government Accountability Office
Publisher : Createspace Independent Publishing Platform
Page : 40 pages
File Size : 55,5 Mb
Release : 2018-01-13
Category : Electronic
ISBN : 1983735604

Get Book

Brand-Name Prescription Drug Pricing by United States Government Accountability Office Pdf

Brand-Name Prescription Drug Pricing: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases

Author : Anonim
Publisher : World Health Organization
Page : 70 pages
File Size : 49,9 Mb
Release : 2020-09-29
Category : Business & Economics
ISBN : 9789240011878

Get Book

WHO guideline on country pharmaceutical pricing policies by Anonim Pdf

In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.

Author : Sarah F. Jaggar
Publisher : Unknown
Page : 12 pages
File Size : 47,8 Mb
Release : 1994
Category : Drugs
ISBN : UOM:39015048868825

Get Book

Prescription Drugs by Sarah F. Jaggar Pdf

Author : Anonim
Publisher : Unknown
Page : 234 pages
File Size : 50,7 Mb
Release : 2000
Category : Drugs
ISBN : STANFORD:36105028431273

Get Book

Report to the President by Anonim Pdf

On October 25,1999, the President directed the Secretary of Health and Human Services to study prescription drug costs and trends for Medicare beneficiaries. He asked that the study investigate: price differences for the most commonly used drugs for people with and without coverage; drug spending by people of various ages, as a percentage of income and of total health spending; and trends in drug expenditures by people of different ages, as a percentage of income and of total health spending. This report is the Department's response to that request. It represents the work of individuals and agencies throughout the Department, including the Agency for Healthcare Research and Quality (AHRQ), the Food and Drug Administration (FDA), the Health Care Financing Administration (HCFA), and the Office of the Assistant Secretary for Planning and Evaluation (ASPE).

Author : Katherine Eban
Publisher : HarperCollins
Page : 512 pages
File Size : 47,9 Mb
Release : 2020-06-23
Category : Medical
ISBN : 9780063054103

Get Book

Bottle of Lies by Katherine Eban Pdf

A NEW YORK TIMES BESTSELLER New York Times 100 Notable Books of 2019 New York Public Library Best Books of 2019 Kirkus Reviews Best Health and Science Books of 2019 Science Friday Best Books of 2019 New postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.

Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Board on Health Care Services
Publisher : National Academies Press
Page : 103 pages
File Size : 44,5 Mb
Release : 2020-01-27
Category : Medical
ISBN : 9780309498517

Get Book

The Role of NIH in Drug Development Innovation and Its Impact on Patient Access by National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Board on Health Care Services Pdf

To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.